Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: An active and tolerable outpatient regimen

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 255-260

  Vaughn, David J ^a   Malkowicz, S Bruce ^a   Zoltick, Barbara ^a   Mick, Rosemarie ^a   Ramchandani, Parvi ^a   Holroyde, Christopher ^a   Armstead, Barbara ^a   Fox, Kevin ^a   Wein, Alan ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CREATININE; PACLITAXEL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG TOLERABILITY; FEMALE; GRANULOCYTOPENIA; HUMAN; KIDNEY DISEASE; MALE; MAXIMUM PERMISSIBLE DOSE; OUTPATIENT CARE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORIMOTOR NEUROPATHY; THROMBOCYTOPENIA; UROGENITAL TRACT TUMOR; UROTHELIUM;

EID: 0031962154     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.255     Document Type: Article

References (19)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1996. CA Cancer J Clin 46:5-27, 1996
2. Malkowicz SB, Vaughn DJ: Chemotherapy for invasive bladder cancer. Urology 47:602-614, 1996
3. Loehrer PJ, Sr., Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 10:1066-1073, 1992
4. Gabrilove JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988
5. Seidman AD, Scher H, Gabrilove JL, et al: Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial carcinoma. J Clin Oncol 11:408-414, 1993
6. Loehrer PJ, Sr., Elson P, Drecier R, et al: Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced bladder carcinoma: An Eastern Cooperative Oncology Group trial. J Clin Oncol 12:483-488, 1994
7. Logothetis CJ, Finn LD, Smith T, et al: Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: Results of a randomized trial. J Clin Oncol 13:2272-2277, 1995
8. Neill HB, Rangel C, Miller A, et al: The activity of antimicrotubular agents in human bladder cancer cell lines. Proc Am Assoc Cancer Res 34:202, 1993 (abstr)
9. Roth BJ, Dreicer R, Einhorn LH, et al: Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group (E1892). J Clin Oncol 12:2264-2270, 1994
10. Waxman J, Barton C: Carboplatin-based chemotherapy for bladder cancer. Cancer Treat Rev 19:21-25, 1993 (suppl C)
11. Petrioli R, Frediani B, Manganelli A, et al: Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. Cancer 77:344-351, 1996
12. Calvert AH, Newell DR, Grumbell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
13. Langer CJ. Leighton JC, Comis RL, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol 13:1860-1870, 1995
14. Bookman MA, McGuire WP III, Kilpatrick D, et al: Carboplatin and paclitaxel in advanced ovarian carcinoma: A phase I study of the Gynecologic Oncology Group. J Clin Oncol 14:1895-1902, 1996
15. Jelliffe RW: Creatinine clearance: Bedside estimate. Ann Intern Med 79:604-605, 1973
16. Guidelines for reporting of adverse drug reactions, in Cancer Therapy Evaluation Division of Cancer Treatment (ed): National Cancer Institute: Investigator's Handbook. Bethesda, MD, United States Department of Health and Human Services, Public Health Service, National Institutes of Health, 1993, Appendix XII
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
18. Dreicer R, Gustin DM, See WA, et al: Paclitaxel in advanced urothelial carcinoma: Its role in patients with renal insufficiency and as salvage therapy. J Urol 156:1606-1608, 1996
19. Kearns CK, Belani CP, Erkmen K, et al: Reduced platelet toxicity with combination carboplatin and paclitaxel; Pharmacodynamic modulation of carboplatin associated thrombocytopenia. Proc Am Soc Clin Oncol 14:170, 1995 (abstr)